Previsión
El precio objetivo medio de los analistas es de 5,47 € (+107,98 %). La mediana es de 5,47 € (+107,98 %).
| Comprar |
5 |
| Mantener |
2 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Protalix reports strong revenue and profit growth in Q2 2026, stock slightly lower premarket
Protalix increased revenue in the second quarter to $19.9 million (+26.8%) and reported a net profit of $3.8 million (EPS $0.05). Product sales were driven primarily by Elfabrio to Chiesi; the company holds $40.7 million in cash and is debt-free. Management reaffirmed the 2026 revenue guidance but noted variable ordering patterns from partners and a pipeline that is still maturing; top-line data for PRX-115 are expected in H2 2027. The stock fell modestly by 0.41% in premarket trading. » Más en de.investing.com
Protalix beats revenue expectations but misses EPS and shares plunge
Protalix reported Q4 2025 revenue of $52.74 million versus expected $18.35 million, but missed on earnings per share at -$0.08 (forecast $0.035). The stock fell about 13% in premarket trading after the company reported a net profit swing to a $6.6 million loss for the fiscal year. Higher R&D costs (+51% to $19.6 million) and increased cost of sales weighed on profitability, while sales to Pfizer supported the strong revenue. Protalix expects a $25 million milestone payment and sees opportunities from a potential European approval of a new Elfabrio dosing regimen. » Más en de.investing.com
Protalix partners with Secarna to develop antisense therapies for rare kidney diseases
Protalix and Secarna have entered a collaboration and option agreement to develop antisense oligonucleotide therapies for rare kidney diseases. Protalix will identify pharmaceutical targets, Secarna will use its AI platform OligoCreator to design candidate molecules, and Protalix will receive an exclusive license option for clinical development and commercialization. The agreement marks Protalix’s first expansion into rare kidney diseases using RNA technologies; financial terms were not disclosed. Protalix also reported a Q3 2025 EPS and revenue miss versus analyst expectations. » Más en de.investing.com
Protalix misses Q3 2025 earnings forecast, stock falls sharply premarket
Protalix reported Q3 2025 earnings per share of $0.03, missing the $0.07 expectation; quarterly revenue was $17.67 million versus an estimated $17.79 million. The stock fell 13.55% in premarket trading to $1.85. For the first nine months, the company reported revenue growth of 24% to $43.6 million and held $29.4 million in cash; Protalix plans to start a phase 2 study for PRX-115 before year-end with initial results expected in Q3 2027. » Más en de.investing.com
Protalix and Chiesi seek re-evaluation of negative EMA opinion on Elfabrio
Protalix and Chiesi Global Rare Diseases have requested a re-evaluation of the EMA’s negative opinion on the proposed alternative dosing regimen for Elfabrio. The aim is to approve an additional option of 2 mg/kg every four weeks alongside the existing 1 mg/kg every two weeks for the treatment of adult patients with Fabry disease. The current marketing authorization remains in effect during the procedure; the final decision will be made by the European Commission after the review is completed. Elfabrio carries a warning for hypersensitivity reactions; Protalix will publish quarterly results on November 17. » Más en de.investing.com
Datos financieros
En el último trimestre, Protalix BioTherapeutics tuvo unos ingresos de 19,36 M € y un beneficio neto de 3,5 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 19,36 M | 27,25 % |
| Beneficio bruto | 12,4 M | 52,78 % |
| Beneficio neto | 3,5 M | 74,26 % |
| EBITDA | 4,47 M | 88,09 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 232,07 M € |
Número de acciones | 84,32 M |
Máximo/mínimo de 52 semanas | 2,91 € - 1,50 € |
| Dividendos | No |
Beta | 0,01 |
Ratio P/E | 11,61 |
Ratio PEG | -0,02 |
Ratio P/B | 3,02 |
Ratio P/S | 3,01 |
Perfil de la empresa
Protalix BioTherapeutics, Inc., una empresa biofarmacéutica, se centra en el desarrollo y la comercialización de proteínas terapéuticas recombinantes basadas en su sistema patentado de expresión de proteínas ProCellEx, a partir de células vegetales, en Estados Unidos, Australia, Canadá, Israel, Brasil, Rusia, Turquía e internacionalmente. La compañía ofrece Elelyso para el tratamiento de la enfermedad de Gaucher. Su cartera de productos comprende PRX-102, una proteína terapéutica candidata, que se encuentra en la última fase de los ensayos clínicos para el tratamiento de la enfermedad de Fabry; PRX-110, una forma recombinante patentada de la desoxirribonucleasa I humana expresada en células vegetales, que ha completado los ensayos clínicos de fase IIa para el tratamiento de la fibrosis quística; PRX-115, una uricasa recombinante PEGilada expresada en células vegetales para el tratamiento de la gota; y PRX-119, un producto candidato de ADNasa I humana recombinante PEGilada expresada en células vegetales para el tratamiento de enfermedades relacionadas con NETs. La compañía tiene acuerdos y alianzas con Pfizer; la Fundação Oswaldo Cruz (Fiocruz); y Chiesi Farmaceutici S.p.A. La empresa fue fundada en 1993 y tiene su sede en Hackensack, Nueva Jersey.
| Nombre | Protalix BioTherapeutics |
| CEO | Dror Bashan |
| Sede | Hackensack,
nj Israel |
| Sitio web | |
| Sector | Consumo básico |
| Industria | Productos alimenticios |
| Salida a bolsa | 15/05/1998 |
| Empleados | 226 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
AMEX | PLX |
Frankfurt | PBDA.F |
Düsseldorf | PBDA.DU |
München | PBDA.MU |